Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067097 | 0.88 | CTSB (0.42) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL3067090 | 0.88 | CTSB (0.42) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL12340397 | 0.84 | CTSB (0.41) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL8110815 | 0.83 | CYP3A4 (0.41) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL7816023 | 0.83 | CYP3A4 (0.41) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL8170871 | 0.78 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL12340378 | 0.78 | ADRB3 (0.41) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13781368 | 0.77 | ADRB3 (0.39) | CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL12340380 | 0.77 | ADRB3 (0.46) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13221905 | 0.76 | CTSB (0.37) | CTSBADRB3ADRA2BADRA2CCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | CTSB 158/4885ADRB3 4195/4885ADRA2B 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.